Objective
To evaluate the cost effectiveness of human papillomavirus vaccine (HPV) for treating cervical cancer.
Methods
We constructed a Markov model to evaluate the cost-effectiveness of HPV versus Chinese healthy women aged 18 to 25 for treating Cervical Cancer. We calculated the clinical benefits and cost-effectiveness and judged the results based on willing to pay. Sensitivity analysis was made for parameters like cost, discounting rate and vaccine efficacy.
Results
HPV vaccination was a cost-effective option under the local willing to pay value with the incremental cost utility ratio 43 489 per QALY gained. It proved that vaccination was an economic and effective solution.
Conclusion
Given the results of Markov model, the cost effectiveness of HPV vaccination of Chinese women aged 18 to 25 is positive. Considering the data sources and model hypothesis, this report has some limitations. Further studies are warranted.
